2658 related articles for article (PubMed ID: 7711115)
1. Tissue-specific transformation by oncogenic mutants of epidermal growth factor receptor.
Carter TH; Kung HJ
Crit Rev Oncog; 1994; 5(4):389-428. PubMed ID: 7711115
[TBL] [Abstract][Full Text] [Related]
2. Disease tropism of c-erbB: effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation.
Pelley RJ; Maihle NJ; Boerkoel C; Shu HK; Carter TH; Moscovici C; Kung HJ
Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7164-8. PubMed ID: 2550929
[TBL] [Abstract][Full Text] [Related]
3. Cell transformation by the epidermal growth factor receptor and v-erbB.
Hayman MJ; Enrietto PJ
Cancer Cells; 1991 Aug; 3(8):302-7. PubMed ID: 1681843
[TBL] [Abstract][Full Text] [Related]
4. Activation of Rho is required for ligand-independent oncogenic signaling by a mutant epidermal growth factor receptor.
Boerner JL; Danielsen A; McManus MJ; Maihle NJ
J Biol Chem; 2001 Feb; 276(5):3691-5. PubMed ID: 11110781
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.
Shu HK; Pelley RJ; Kung HJ
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168
[TBL] [Abstract][Full Text] [Related]
6. Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.
Cho J; Kim S; Du J; Meyerson M
Int J Cancer; 2018 Aug; 143(3):679-685. PubMed ID: 29464683
[TBL] [Abstract][Full Text] [Related]
7. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
Danielsen AJ; Maihle NJ
Exp Cell Res; 2002 Apr; 275(1):9-16. PubMed ID: 11925101
[TBL] [Abstract][Full Text] [Related]
8. Ras-independent oncogenic transformation by an EGF-receptor mutant.
Boerner JL; McManus MJ; Martin GS; Maihle NJ
J Cell Sci; 2000 Mar; 113 ( Pt 6)():935-42. PubMed ID: 10683142
[TBL] [Abstract][Full Text] [Related]
9. Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts.
Khazaie K; Dull TJ; Graf T; Schlessinger J; Ullrich A; Beug H; Vennström B
EMBO J; 1988 Oct; 7(10):3061-71. PubMed ID: 3263272
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the role of the carboxy-terminal region of the v-erbB protein in erythroid cell transformation.
Lee EB; Beug H; Hayman MJ
Oncogene; 1993 May; 8(5):1317-27. PubMed ID: 8097581
[TBL] [Abstract][Full Text] [Related]
11. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm.
Boerner JL; Danielsen A; Maihle NJ
Exp Cell Res; 2003 Mar; 284(1):111-21. PubMed ID: 12648470
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of neoplastic transformation by the retroviral oncogene v-erbB.
Wells A; Bishop JM
Proc Natl Acad Sci U S A; 1988 Oct; 85(20):7597-601. PubMed ID: 2902633
[TBL] [Abstract][Full Text] [Related]
13. A chimeric, ligand-binding v-erbB/EGF receptor retains transforming potential.
Riedel H; Schlessinger J; Ullrich A
Science; 1987 Apr; 236(4798):197-200. PubMed ID: 3494307
[TBL] [Abstract][Full Text] [Related]
14. Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions.
Adelsman MA; Huntley BK; Maihle NJ
J Virol; 1996 Apr; 70(4):2533-44. PubMed ID: 8642683
[TBL] [Abstract][Full Text] [Related]
15. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
16. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Park AK; Francis JM; Park WY; Park JO; Cho J
Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
[TBL] [Abstract][Full Text] [Related]
17. The EGF receptor: structure, regulation and potential role in malignancy.
Thompson DM; Gill GN
Cancer Surv; 1985; 4(4):767-88. PubMed ID: 2824044
[TBL] [Abstract][Full Text] [Related]
18. Resistance to transformation by insertionally activated c-erbB is a dominant phenotype in fibroblasts.
Carter TH; Dominguez N; Zeng L; Kung HJ
Virology; 1995 Sep; 212(1):277-83. PubMed ID: 7676646
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor and its receptor.
Gill GN; Bertics PJ; Santon JB
Mol Cell Endocrinol; 1987 Jun; 51(3):169-86. PubMed ID: 3109978
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms involving an expanding erbB/EGF receptor family of tyrosine kinases in human neoplasia.
Di Fiore PP; Kraus MH
Cancer Treat Res; 1992; 61():139-60. PubMed ID: 1360229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
